nodes	percent_of_prediction	percent_of_DWPC	metapath
Haloperidol—CYP1A2—Imiquimod—skin cancer	0.0788	0.111	CbGbCtD
Haloperidol—CYP1A1—Dacarbazine—skin cancer	0.0741	0.104	CbGbCtD
Haloperidol—CYP2C19—Vismodegib—skin cancer	0.0592	0.0833	CbGbCtD
Haloperidol—CYP2C9—Vismodegib—skin cancer	0.0492	0.0693	CbGbCtD
Haloperidol—ABCB1—Vismodegib—skin cancer	0.0478	0.0672	CbGbCtD
Haloperidol—CYP1A2—Vemurafenib—skin cancer	0.0432	0.0608	CbGbCtD
Haloperidol—CYP3A4—Imiquimod—skin cancer	0.0413	0.0581	CbGbCtD
Haloperidol—CYP3A4—Temozolomide—skin cancer	0.0413	0.0581	CbGbCtD
Haloperidol—CYP2D6—Vemurafenib—skin cancer	0.0356	0.0501	CbGbCtD
Haloperidol—CYP1A2—Dacarbazine—skin cancer	0.0331	0.0466	CbGbCtD
Haloperidol—CYP3A4—Vismodegib—skin cancer	0.0286	0.0403	CbGbCtD
Haloperidol—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0265	0.0374	CbGbCtD
Haloperidol—CYP3A7—Docetaxel—skin cancer	0.0265	0.0374	CbGbCtD
Haloperidol—ABCB1—Dactinomycin—skin cancer	0.0251	0.0353	CbGbCtD
Haloperidol—CYP3A4—Vemurafenib—skin cancer	0.0226	0.0318	CbGbCtD
Haloperidol—CYP3A5—Docetaxel—skin cancer	0.0199	0.028	CbGbCtD
Haloperidol—CYP1A2—Fluorouracil—skin cancer	0.0194	0.0273	CbGbCtD
Haloperidol—CYP2C9—Fluorouracil—skin cancer	0.0175	0.0246	CbGbCtD
Haloperidol—ABCB1—Docetaxel—skin cancer	0.013	0.0182	CbGbCtD
Haloperidol—CYP3A4—Docetaxel—skin cancer	0.00777	0.0109	CbGbCtD
Haloperidol—Dyclonine—SCN10A—skin cancer	0.00648	1	CrCbGaD
Haloperidol—GRIN2B—nerve—skin cancer	0.00515	0.0656	CbGeAlD
Haloperidol—HRH1—nose—skin cancer	0.00504	0.0641	CbGeAlD
Haloperidol—EBP—Sorafenib—Vismodegib—skin cancer	0.00474	1	CbGdCrCtD
Haloperidol—DRD1—nerve—skin cancer	0.00309	0.0393	CbGeAlD
Haloperidol—H1F0—hair follicle—skin cancer	0.00262	0.0334	CbGeAlD
Haloperidol—EBP—female reproductive system—skin cancer	0.00238	0.0303	CbGeAlD
Haloperidol—CBR1—nipple—skin cancer	0.00217	0.0276	CbGeAlD
Haloperidol—HTR2A—hindlimb—skin cancer	0.00198	0.0252	CbGeAlD
Haloperidol—HTR1B—blood vessel—skin cancer	0.00197	0.025	CbGeAlD
Haloperidol—HTR1D—blood vessel—skin cancer	0.00191	0.0242	CbGeAlD
Haloperidol—DRD2—nerve—skin cancer	0.00183	0.0232	CbGeAlD
Haloperidol—CYP1A1—skin epidermis—skin cancer	0.00178	0.0227	CbGeAlD
Haloperidol—H1F0—nipple—skin cancer	0.00178	0.0226	CbGeAlD
Haloperidol—H1F0—neck—skin cancer	0.00176	0.0224	CbGeAlD
Haloperidol—HTR2A—appendage—skin cancer	0.0017	0.0216	CbGeAlD
Haloperidol—CBR1—skin of body—skin cancer	0.00139	0.0177	CbGeAlD
Haloperidol—SIGMAR1—nipple—skin cancer	0.00128	0.0163	CbGeAlD
Haloperidol—CBR1—mammalian vulva—skin cancer	0.00127	0.0161	CbGeAlD
Haloperidol—H1F0—connective tissue—skin cancer	0.00126	0.016	CbGeAlD
Haloperidol—GRIN2B—head—skin cancer	0.00122	0.0156	CbGeAlD
Haloperidol—HTR2A—nerve—skin cancer	0.00121	0.0153	CbGeAlD
Haloperidol—H1F0—skin of body—skin cancer	0.00114	0.0145	CbGeAlD
Haloperidol—CBR1—lymphoid tissue—skin cancer	0.00113	0.0143	CbGeAlD
Haloperidol—CBR1—female reproductive system—skin cancer	0.00109	0.0138	CbGeAlD
Haloperidol—H1F0—mammalian vulva—skin cancer	0.00104	0.0132	CbGeAlD
Haloperidol—HTR2A—endothelium—skin cancer	0.00103	0.0131	CbGeAlD
Haloperidol—DRD3—head—skin cancer	0.00102	0.013	CbGeAlD
Haloperidol—KCNH2—nipple—skin cancer	0.00102	0.013	CbGeAlD
Haloperidol—HTR1D—connective tissue—skin cancer	0.000977	0.0124	CbGeAlD
Haloperidol—HTR2A—blood vessel—skin cancer	0.000947	0.012	CbGeAlD
Haloperidol—H1F0—lymphoid tissue—skin cancer	0.000922	0.0117	CbGeAlD
Haloperidol—CBR1—head—skin cancer	0.000907	0.0115	CbGeAlD
Haloperidol—H1F0—female reproductive system—skin cancer	0.000889	0.0113	CbGeAlD
Haloperidol—CYP1A2—nipple—skin cancer	0.000875	0.0111	CbGeAlD
Haloperidol—CYP1A1—nipple—skin cancer	0.000863	0.011	CbGeAlD
Haloperidol—HTR2B—skin of body—skin cancer	0.000821	0.0104	CbGeAlD
Haloperidol—HRH1—nipple—skin cancer	0.000819	0.0104	CbGeAlD
Haloperidol—SIGMAR1—mammalian vulva—skin cancer	0.00075	0.00954	CbGeAlD
Haloperidol—H1F0—head—skin cancer	0.000743	0.00945	CbGeAlD
Haloperidol—DRD1—head—skin cancer	0.000734	0.00933	CbGeAlD
Haloperidol—HTR1B—female reproductive system—skin cancer	0.000712	0.00905	CbGeAlD
Haloperidol—HTR1D—female reproductive system—skin cancer	0.000689	0.00876	CbGeAlD
Haloperidol—HTR2A—neck—skin cancer	0.000677	0.00861	CbGeAlD
Haloperidol—Nervous system disorder—Vemurafenib—skin cancer	0.000659	0.00365	CcSEcCtD
Haloperidol—Lethargy—Fluorouracil—skin cancer	0.000657	0.00364	CcSEcCtD
Haloperidol—Skin disorder—Vemurafenib—skin cancer	0.000653	0.00361	CcSEcCtD
Haloperidol—Weight decreased—Bleomycin—skin cancer	0.000648	0.00358	CcSEcCtD
Haloperidol—Nausea—Vismodegib—skin cancer	0.000646	0.00358	CcSEcCtD
Haloperidol—Agitation—Imiquimod—skin cancer	0.000645	0.00357	CcSEcCtD
Haloperidol—HTR2B—female reproductive system—skin cancer	0.000641	0.00815	CbGeAlD
Haloperidol—Injection site reaction—Docetaxel—skin cancer	0.000636	0.00352	CcSEcCtD
Haloperidol—CBR1—lymph node—skin cancer	0.000635	0.00808	CbGeAlD
Haloperidol—Pancytopenia—Dactinomycin—skin cancer	0.000634	0.00351	CcSEcCtD
Haloperidol—Breast disorder—Temozolomide—skin cancer	0.000631	0.00349	CcSEcCtD
Haloperidol—Hypotension—Vemurafenib—skin cancer	0.000628	0.00347	CcSEcCtD
Haloperidol—Neutropenia—Dactinomycin—skin cancer	0.000624	0.00345	CcSEcCtD
Haloperidol—ABCB1—blood vessel—skin cancer	0.00062	0.00789	CbGeAlD
Haloperidol—Cardiac arrest—Fluorouracil—skin cancer	0.000612	0.00339	CcSEcCtD
Haloperidol—Convulsion—Imiquimod—skin cancer	0.000608	0.00337	CcSEcCtD
Haloperidol—Hypertension—Imiquimod—skin cancer	0.000606	0.00335	CcSEcCtD
Haloperidol—Dysphagia—Temozolomide—skin cancer	0.000604	0.00334	CcSEcCtD
Haloperidol—Anxiety—Imiquimod—skin cancer	0.000596	0.0033	CcSEcCtD
Haloperidol—HTR1B—head—skin cancer	0.000595	0.00756	CbGeAlD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000594	0.00329	CcSEcCtD
Haloperidol—Sweating increased—Temozolomide—skin cancer	0.000588	0.00326	CcSEcCtD
Haloperidol—Dry mouth—Imiquimod—skin cancer	0.000585	0.00324	CcSEcCtD
Haloperidol—Decreased appetite—Vemurafenib—skin cancer	0.000584	0.00323	CcSEcCtD
Haloperidol—CYP1A1—epithelium—skin cancer	0.000581	0.00739	CbGeAlD
Haloperidol—HRH1—connective tissue—skin cancer	0.000581	0.00739	CbGeAlD
Haloperidol—Gastrointestinal disorder—Vemurafenib—skin cancer	0.00058	0.00321	CcSEcCtD
Haloperidol—HTR1D—head—skin cancer	0.000576	0.00732	CbGeAlD
Haloperidol—Constipation—Vemurafenib—skin cancer	0.000574	0.00318	CcSEcCtD
Haloperidol—Pancytopenia—Temozolomide—skin cancer	0.000573	0.00317	CcSEcCtD
Haloperidol—Oedema—Imiquimod—skin cancer	0.000573	0.00317	CcSEcCtD
Haloperidol—Neutropenia—Temozolomide—skin cancer	0.000565	0.00312	CcSEcCtD
Haloperidol—Nervous system disorder—Imiquimod—skin cancer	0.000562	0.00311	CcSEcCtD
Haloperidol—Tachycardia—Imiquimod—skin cancer	0.000559	0.00309	CcSEcCtD
Haloperidol—Skin disorder—Imiquimod—skin cancer	0.000557	0.00308	CcSEcCtD
Haloperidol—Dysphagia—Fluorouracil—skin cancer	0.000556	0.00308	CcSEcCtD
Haloperidol—Erectile dysfunction—Temozolomide—skin cancer	0.000556	0.00308	CcSEcCtD
Haloperidol—Agranulocytosis—Dactinomycin—skin cancer	0.000555	0.00307	CcSEcCtD
Haloperidol—Hyperhidrosis—Imiquimod—skin cancer	0.000554	0.00307	CcSEcCtD
Haloperidol—CYP1A1—skin of body—skin cancer	0.000553	0.00703	CbGeAlD
Haloperidol—HRH1—epithelium—skin cancer	0.000552	0.00702	CbGeAlD
Haloperidol—Photosensitivity reaction—Temozolomide—skin cancer	0.000551	0.00305	CcSEcCtD
Haloperidol—Weight increased—Temozolomide—skin cancer	0.000549	0.00304	CcSEcCtD
Haloperidol—Weight decreased—Temozolomide—skin cancer	0.000546	0.00302	CcSEcCtD
Haloperidol—Anorexia—Imiquimod—skin cancer	0.000546	0.00302	CcSEcCtD
Haloperidol—Hyperglycaemia—Temozolomide—skin cancer	0.000545	0.00301	CcSEcCtD
Haloperidol—Depression—Temozolomide—skin cancer	0.000537	0.00297	CcSEcCtD
Haloperidol—HTR2B—head—skin cancer	0.000535	0.00681	CbGeAlD
Haloperidol—Hepatitis—Dactinomycin—skin cancer	0.000534	0.00296	CcSEcCtD
Haloperidol—Body temperature increased—Vemurafenib—skin cancer	0.000531	0.00294	CcSEcCtD
Haloperidol—Pancytopenia—Fluorouracil—skin cancer	0.000528	0.00292	CcSEcCtD
Haloperidol—H1F0—lymph node—skin cancer	0.00052	0.00662	CbGeAlD
Haloperidol—Insomnia—Imiquimod—skin cancer	0.000518	0.00287	CcSEcCtD
Haloperidol—KCNH2—female reproductive system—skin cancer	0.000511	0.0065	CbGeAlD
Haloperidol—Dyspnoea—Imiquimod—skin cancer	0.000511	0.00283	CcSEcCtD
Haloperidol—Somnolence—Imiquimod—skin cancer	0.000509	0.00282	CcSEcCtD
Haloperidol—Hepatobiliary disease—Temozolomide—skin cancer	0.000509	0.00282	CcSEcCtD
Haloperidol—Photosensitivity reaction—Fluorouracil—skin cancer	0.000508	0.00281	CcSEcCtD
Haloperidol—Alopecia—Bleomycin—skin cancer	0.000506	0.0028	CcSEcCtD
Haloperidol—Dyspepsia—Imiquimod—skin cancer	0.000504	0.00279	CcSEcCtD
Haloperidol—CYP1A1—mammalian vulva—skin cancer	0.000504	0.00641	CbGeAlD
Haloperidol—Decreased appetite—Imiquimod—skin cancer	0.000498	0.00276	CcSEcCtD
Haloperidol—Hypersensitivity—Vemurafenib—skin cancer	0.000495	0.00274	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Imiquimod—skin cancer	0.000495	0.00274	CcSEcCtD
Haloperidol—Visual disturbance—Docetaxel—skin cancer	0.00049	0.00271	CcSEcCtD
Haloperidol—HTR2A—connective tissue—skin cancer	0.000485	0.00617	CbGeAlD
Haloperidol—Hepatitis—Temozolomide—skin cancer	0.000483	0.00267	CcSEcCtD
Haloperidol—Hallucination—Temozolomide—skin cancer	0.000481	0.00266	CcSEcCtD
Haloperidol—HRH1—mammalian vulva—skin cancer	0.000479	0.00609	CbGeAlD
Haloperidol—Urinary tract disorder—Temozolomide—skin cancer	0.000477	0.00264	CcSEcCtD
Haloperidol—Pruritus—Vemurafenib—skin cancer	0.000475	0.00263	CcSEcCtD
Haloperidol—Connective tissue disorder—Temozolomide—skin cancer	0.000475	0.00263	CcSEcCtD
Haloperidol—Lethargy—Docetaxel—skin cancer	0.000474	0.00262	CcSEcCtD
Haloperidol—Urethral disorder—Temozolomide—skin cancer	0.000474	0.00262	CcSEcCtD
Haloperidol—Alopecia—Dactinomycin—skin cancer	0.000472	0.00261	CcSEcCtD
Haloperidol—Feeling abnormal—Imiquimod—skin cancer	0.000472	0.00261	CcSEcCtD
Haloperidol—Hyponatraemia—Docetaxel—skin cancer	0.000466	0.00258	CcSEcCtD
Haloperidol—Visual impairment—Temozolomide—skin cancer	0.000466	0.00258	CcSEcCtD
Haloperidol—Agranulocytosis—Fluorouracil—skin cancer	0.000463	0.00256	CcSEcCtD
Haloperidol—Anaemia—Bleomycin—skin cancer	0.000461	0.00255	CcSEcCtD
Haloperidol—HTR2A—epithelium—skin cancer	0.000461	0.00586	CbGeAlD
Haloperidol—Diarrhoea—Vemurafenib—skin cancer	0.00046	0.00254	CcSEcCtD
Haloperidol—Urticaria—Imiquimod—skin cancer	0.000455	0.00252	CcSEcCtD
Haloperidol—Body temperature increased—Imiquimod—skin cancer	0.000453	0.00251	CcSEcCtD
Haloperidol—Eye disorder—Temozolomide—skin cancer	0.000452	0.0025	CcSEcCtD
Haloperidol—Cardiac disorder—Temozolomide—skin cancer	0.000449	0.00248	CcSEcCtD
Haloperidol—Leukopenia—Bleomycin—skin cancer	0.000446	0.00247	CcSEcCtD
Haloperidol—Dizziness—Vemurafenib—skin cancer	0.000444	0.00246	CcSEcCtD
Haloperidol—Angiopathy—Temozolomide—skin cancer	0.000438	0.00243	CcSEcCtD
Haloperidol—Immune system disorder—Temozolomide—skin cancer	0.000437	0.00242	CcSEcCtD
Haloperidol—Mediastinal disorder—Temozolomide—skin cancer	0.000436	0.00241	CcSEcCtD
Haloperidol—DRD2—head—skin cancer	0.000434	0.00551	CbGeAlD
Haloperidol—CYP1A1—female reproductive system—skin cancer	0.000432	0.00549	CbGeAlD
Haloperidol—Anaemia—Dactinomycin—skin cancer	0.00043	0.00238	CcSEcCtD
Haloperidol—Liver function test abnormal—Docetaxel—skin cancer	0.000429	0.00237	CcSEcCtD
Haloperidol—Vomiting—Vemurafenib—skin cancer	0.000427	0.00236	CcSEcCtD
Haloperidol—KCNH2—head—skin cancer	0.000427	0.00543	CbGeAlD
Haloperidol—Alopecia—Temozolomide—skin cancer	0.000427	0.00236	CcSEcCtD
Haloperidol—Orthostatic hypotension—Docetaxel—skin cancer	0.000424	0.00235	CcSEcCtD
Haloperidol—Rash—Vemurafenib—skin cancer	0.000424	0.00234	CcSEcCtD
Haloperidol—Mental disorder—Temozolomide—skin cancer	0.000423	0.00234	CcSEcCtD
Haloperidol—Dermatitis—Vemurafenib—skin cancer	0.000423	0.00234	CcSEcCtD
Haloperidol—Hypersensitivity—Imiquimod—skin cancer	0.000422	0.00234	CcSEcCtD
Haloperidol—Headache—Vemurafenib—skin cancer	0.000421	0.00233	CcSEcCtD
Haloperidol—Malnutrition—Temozolomide—skin cancer	0.000421	0.00233	CcSEcCtD
Haloperidol—Breast disorder—Docetaxel—skin cancer	0.00042	0.00232	CcSEcCtD
Haloperidol—Leukopenia—Dactinomycin—skin cancer	0.000416	0.0023	CcSEcCtD
Haloperidol—CYP2C9—female reproductive system—skin cancer	0.000416	0.00528	CbGeAlD
Haloperidol—Confusional state—Bleomycin—skin cancer	0.00041	0.00227	CcSEcCtD
Haloperidol—HRH1—female reproductive system—skin cancer	0.00041	0.00521	CbGeAlD
Haloperidol—Oedema—Bleomycin—skin cancer	0.000407	0.00225	CcSEcCtD
Haloperidol—Anaphylactic shock—Bleomycin—skin cancer	0.000407	0.00225	CcSEcCtD
Haloperidol—Pruritus—Imiquimod—skin cancer	0.000405	0.00224	CcSEcCtD
Haloperidol—Dysphagia—Docetaxel—skin cancer	0.000402	0.00222	CcSEcCtD
Haloperidol—Nausea—Vemurafenib—skin cancer	0.000399	0.00221	CcSEcCtD
Haloperidol—Thrombocytopenia—Bleomycin—skin cancer	0.000399	0.00221	CcSEcCtD
Haloperidol—Vision blurred—Temozolomide—skin cancer	0.000396	0.00219	CcSEcCtD
Haloperidol—Bronchospasm—Docetaxel—skin cancer	0.000395	0.00219	CcSEcCtD
Haloperidol—Tremor—Temozolomide—skin cancer	0.000394	0.00218	CcSEcCtD
Haloperidol—Alopecia—Fluorouracil—skin cancer	0.000393	0.00218	CcSEcCtD
Haloperidol—Diarrhoea—Imiquimod—skin cancer	0.000392	0.00217	CcSEcCtD
Haloperidol—Anaemia—Temozolomide—skin cancer	0.000389	0.00215	CcSEcCtD
Haloperidol—Anorexia—Bleomycin—skin cancer	0.000388	0.00215	CcSEcCtD
Haloperidol—Agitation—Temozolomide—skin cancer	0.000387	0.00214	CcSEcCtD
Haloperidol—Pancytopenia—Docetaxel—skin cancer	0.000381	0.00211	CcSEcCtD
Haloperidol—Hypotension—Bleomycin—skin cancer	0.00038	0.00211	CcSEcCtD
Haloperidol—Oedema—Dactinomycin—skin cancer	0.00038	0.0021	CcSEcCtD
Haloperidol—Dizziness—Imiquimod—skin cancer	0.000379	0.0021	CcSEcCtD
Haloperidol—Vertigo—Temozolomide—skin cancer	0.000378	0.00209	CcSEcCtD
Haloperidol—Leukopenia—Temozolomide—skin cancer	0.000377	0.00208	CcSEcCtD
Haloperidol—SIGMAR1—lymph node—skin cancer	0.000376	0.00478	CbGeAlD
Haloperidol—Neutropenia—Docetaxel—skin cancer	0.000375	0.00208	CcSEcCtD
Haloperidol—HTR2B—lymph node—skin cancer	0.000375	0.00477	CbGeAlD
Haloperidol—Thrombocytopenia—Dactinomycin—skin cancer	0.000372	0.00206	CcSEcCtD
Haloperidol—Weight increased—Docetaxel—skin cancer	0.000365	0.00202	CcSEcCtD
Haloperidol—Vision blurred—Fluorouracil—skin cancer	0.000365	0.00202	CcSEcCtD
Haloperidol—Convulsion—Temozolomide—skin cancer	0.000364	0.00202	CcSEcCtD
Haloperidol—Vomiting—Imiquimod—skin cancer	0.000364	0.00202	CcSEcCtD
Haloperidol—Weight decreased—Docetaxel—skin cancer	0.000363	0.00201	CcSEcCtD
Haloperidol—Hypertension—Temozolomide—skin cancer	0.000363	0.00201	CcSEcCtD
Haloperidol—Dyspnoea—Bleomycin—skin cancer	0.000363	0.00201	CcSEcCtD
Haloperidol—Anorexia—Dactinomycin—skin cancer	0.000362	0.002	CcSEcCtD
Haloperidol—Rash—Imiquimod—skin cancer	0.000361	0.002	CcSEcCtD
Haloperidol—Dermatitis—Imiquimod—skin cancer	0.000361	0.002	CcSEcCtD
Haloperidol—CYP1A1—head—skin cancer	0.000361	0.00459	CbGeAlD
Haloperidol—Headache—Imiquimod—skin cancer	0.000359	0.00199	CcSEcCtD
Haloperidol—Anaemia—Fluorouracil—skin cancer	0.000358	0.00198	CcSEcCtD
Haloperidol—Anxiety—Temozolomide—skin cancer	0.000357	0.00198	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000356	0.00197	CcSEcCtD
Haloperidol—Decreased appetite—Bleomycin—skin cancer	0.000354	0.00196	CcSEcCtD
Haloperidol—Dry mouth—Temozolomide—skin cancer	0.00035	0.00194	CcSEcCtD
Haloperidol—Jaundice—Docetaxel—skin cancer	0.000349	0.00193	CcSEcCtD
Haloperidol—Leukopenia—Fluorouracil—skin cancer	0.000347	0.00192	CcSEcCtD
Haloperidol—Confusional state—Temozolomide—skin cancer	0.000346	0.00192	CcSEcCtD
Haloperidol—Oedema—Temozolomide—skin cancer	0.000343	0.0019	CcSEcCtD
Haloperidol—Anaphylactic shock—Temozolomide—skin cancer	0.000343	0.0019	CcSEcCtD
Haloperidol—HRH1—head—skin cancer	0.000342	0.00435	CbGeAlD
Haloperidol—HTR2A—female reproductive system—skin cancer	0.000342	0.00435	CbGeAlD
Haloperidol—Nausea—Imiquimod—skin cancer	0.00034	0.00188	CcSEcCtD
Haloperidol—Hepatobiliary disease—Docetaxel—skin cancer	0.000339	0.00187	CcSEcCtD
Haloperidol—Nervous system disorder—Temozolomide—skin cancer	0.000337	0.00186	CcSEcCtD
Haloperidol—Thrombocytopenia—Temozolomide—skin cancer	0.000336	0.00186	CcSEcCtD
Haloperidol—Convulsion—Fluorouracil—skin cancer	0.000336	0.00186	CcSEcCtD
Haloperidol—Feeling abnormal—Bleomycin—skin cancer	0.000335	0.00186	CcSEcCtD
Haloperidol—Agranulocytosis—Docetaxel—skin cancer	0.000334	0.00185	CcSEcCtD
Haloperidol—Skin disorder—Temozolomide—skin cancer	0.000333	0.00185	CcSEcCtD
Haloperidol—Hyperhidrosis—Temozolomide—skin cancer	0.000332	0.00184	CcSEcCtD
Haloperidol—Decreased appetite—Dactinomycin—skin cancer	0.00033	0.00183	CcSEcCtD
Haloperidol—Anorexia—Temozolomide—skin cancer	0.000327	0.00181	CcSEcCtD
Haloperidol—Urticaria—Bleomycin—skin cancer	0.000323	0.00179	CcSEcCtD
Haloperidol—Body temperature increased—Bleomycin—skin cancer	0.000322	0.00178	CcSEcCtD
Haloperidol—Hepatitis—Docetaxel—skin cancer	0.000321	0.00178	CcSEcCtD
Haloperidol—Confusional state—Fluorouracil—skin cancer	0.000319	0.00177	CcSEcCtD
Haloperidol—Urinary tract disorder—Docetaxel—skin cancer	0.000317	0.00176	CcSEcCtD
Haloperidol—CYP3A4—female reproductive system—skin cancer	0.000317	0.00403	CbGeAlD
Haloperidol—Anaphylactic shock—Fluorouracil—skin cancer	0.000316	0.00175	CcSEcCtD
Haloperidol—Oedema—Fluorouracil—skin cancer	0.000316	0.00175	CcSEcCtD
Haloperidol—Connective tissue disorder—Docetaxel—skin cancer	0.000316	0.00175	CcSEcCtD
Haloperidol—Urethral disorder—Docetaxel—skin cancer	0.000315	0.00174	CcSEcCtD
Haloperidol—Feeling abnormal—Dactinomycin—skin cancer	0.000313	0.00173	CcSEcCtD
Haloperidol—CYP2D6—female reproductive system—skin cancer	0.000312	0.00397	CbGeAlD
Haloperidol—Insomnia—Temozolomide—skin cancer	0.000311	0.00172	CcSEcCtD
Haloperidol—Nervous system disorder—Fluorouracil—skin cancer	0.00031	0.00172	CcSEcCtD
Haloperidol—Thrombocytopenia—Fluorouracil—skin cancer	0.00031	0.00171	CcSEcCtD
Haloperidol—Visual impairment—Docetaxel—skin cancer	0.00031	0.00171	CcSEcCtD
Haloperidol—Tachycardia—Fluorouracil—skin cancer	0.000309	0.00171	CcSEcCtD
Haloperidol—Dyspnoea—Temozolomide—skin cancer	0.000306	0.00169	CcSEcCtD
Haloperidol—Somnolence—Temozolomide—skin cancer	0.000305	0.00169	CcSEcCtD
Haloperidol—Dyspepsia—Temozolomide—skin cancer	0.000302	0.00167	CcSEcCtD
Haloperidol—ABCB1—epithelium—skin cancer	0.000302	0.00384	CbGeAlD
Haloperidol—Anorexia—Fluorouracil—skin cancer	0.000302	0.00167	CcSEcCtD
Haloperidol—Eye disorder—Docetaxel—skin cancer	0.0003	0.00166	CcSEcCtD
Haloperidol—Body temperature increased—Dactinomycin—skin cancer	0.0003	0.00166	CcSEcCtD
Haloperidol—Hypersensitivity—Bleomycin—skin cancer	0.0003	0.00166	CcSEcCtD
Haloperidol—KCNH2—lymph node—skin cancer	0.000299	0.0038	CbGeAlD
Haloperidol—Decreased appetite—Temozolomide—skin cancer	0.000298	0.00165	CcSEcCtD
Haloperidol—Cardiac disorder—Docetaxel—skin cancer	0.000298	0.00165	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Temozolomide—skin cancer	0.000296	0.00164	CcSEcCtD
Haloperidol—Hypotension—Fluorouracil—skin cancer	0.000296	0.00164	CcSEcCtD
Haloperidol—Constipation—Temozolomide—skin cancer	0.000294	0.00163	CcSEcCtD
Haloperidol—Angiopathy—Docetaxel—skin cancer	0.000292	0.00161	CcSEcCtD
Haloperidol—Immune system disorder—Docetaxel—skin cancer	0.00029	0.00161	CcSEcCtD
Haloperidol—Mediastinal disorder—Docetaxel—skin cancer	0.00029	0.0016	CcSEcCtD
Haloperidol—Pruritus—Bleomycin—skin cancer	0.000288	0.00159	CcSEcCtD
Haloperidol—Insomnia—Fluorouracil—skin cancer	0.000286	0.00158	CcSEcCtD
Haloperidol—HTR2A—head—skin cancer	0.000286	0.00364	CbGeAlD
Haloperidol—Alopecia—Docetaxel—skin cancer	0.000284	0.00157	CcSEcCtD
Haloperidol—Feeling abnormal—Temozolomide—skin cancer	0.000283	0.00157	CcSEcCtD
Haloperidol—Dyspnoea—Fluorouracil—skin cancer	0.000282	0.00156	CcSEcCtD
Haloperidol—Mental disorder—Docetaxel—skin cancer	0.000282	0.00156	CcSEcCtD
Haloperidol—Somnolence—Fluorouracil—skin cancer	0.000281	0.00156	CcSEcCtD
Haloperidol—Malnutrition—Docetaxel—skin cancer	0.00028	0.00155	CcSEcCtD
Haloperidol—Hypersensitivity—Dactinomycin—skin cancer	0.00028	0.00155	CcSEcCtD
Haloperidol—Dyspepsia—Fluorouracil—skin cancer	0.000278	0.00154	CcSEcCtD
Haloperidol—Decreased appetite—Fluorouracil—skin cancer	0.000275	0.00152	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000273	0.00151	CcSEcCtD
Haloperidol—Urticaria—Temozolomide—skin cancer	0.000273	0.00151	CcSEcCtD
Haloperidol—Body temperature increased—Temozolomide—skin cancer	0.000271	0.0015	CcSEcCtD
Haloperidol—Muscle spasms—Docetaxel—skin cancer	0.000269	0.00149	CcSEcCtD
Haloperidol—ABCB1—mammalian vulva—skin cancer	0.000262	0.00333	CbGeAlD
Haloperidol—Feeling abnormal—Fluorouracil—skin cancer	0.000261	0.00144	CcSEcCtD
Haloperidol—CYP2D6—head—skin cancer	0.00026	0.00331	CbGeAlD
Haloperidol—Diarrhoea—Dactinomycin—skin cancer	0.00026	0.00144	CcSEcCtD
Haloperidol—Vomiting—Bleomycin—skin cancer	0.000259	0.00143	CcSEcCtD
Haloperidol—Anaemia—Docetaxel—skin cancer	0.000259	0.00143	CcSEcCtD
Haloperidol—Rash—Bleomycin—skin cancer	0.000257	0.00142	CcSEcCtD
Haloperidol—Dermatitis—Bleomycin—skin cancer	0.000256	0.00142	CcSEcCtD
Haloperidol—Hypersensitivity—Temozolomide—skin cancer	0.000253	0.0014	CcSEcCtD
Haloperidol—CYP1A1—lymph node—skin cancer	0.000253	0.00321	CbGeAlD
Haloperidol—Urticaria—Fluorouracil—skin cancer	0.000251	0.00139	CcSEcCtD
Haloperidol—Leukopenia—Docetaxel—skin cancer	0.00025	0.00139	CcSEcCtD
Haloperidol—Body temperature increased—Fluorouracil—skin cancer	0.00025	0.00138	CcSEcCtD
Haloperidol—Pruritus—Temozolomide—skin cancer	0.000243	0.00134	CcSEcCtD
Haloperidol—Convulsion—Docetaxel—skin cancer	0.000242	0.00134	CcSEcCtD
Haloperidol—Nausea—Bleomycin—skin cancer	0.000242	0.00134	CcSEcCtD
Haloperidol—Hypertension—Docetaxel—skin cancer	0.000242	0.00134	CcSEcCtD
Haloperidol—Vomiting—Dactinomycin—skin cancer	0.000241	0.00134	CcSEcCtD
Haloperidol—HRH1—lymph node—skin cancer	0.00024	0.00305	CbGeAlD
Haloperidol—Rash—Dactinomycin—skin cancer	0.000239	0.00132	CcSEcCtD
Haloperidol—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000237	0.00131	CcSEcCtD
Haloperidol—Diarrhoea—Temozolomide—skin cancer	0.000235	0.0013	CcSEcCtD
Haloperidol—Hypersensitivity—Fluorouracil—skin cancer	0.000233	0.00129	CcSEcCtD
Haloperidol—Dry mouth—Docetaxel—skin cancer	0.000233	0.00129	CcSEcCtD
Haloperidol—ABCB1—lymphoid tissue—skin cancer	0.000233	0.00296	CbGeAlD
Haloperidol—Confusional state—Docetaxel—skin cancer	0.00023	0.00127	CcSEcCtD
Haloperidol—Anaphylactic shock—Docetaxel—skin cancer	0.000228	0.00126	CcSEcCtD
Haloperidol—Oedema—Docetaxel—skin cancer	0.000228	0.00126	CcSEcCtD
Haloperidol—Dizziness—Temozolomide—skin cancer	0.000227	0.00126	CcSEcCtD
Haloperidol—Nausea—Dactinomycin—skin cancer	0.000225	0.00125	CcSEcCtD
Haloperidol—ABCB1—female reproductive system—skin cancer	0.000224	0.00285	CbGeAlD
Haloperidol—Nervous system disorder—Docetaxel—skin cancer	0.000224	0.00124	CcSEcCtD
Haloperidol—Pruritus—Fluorouracil—skin cancer	0.000224	0.00124	CcSEcCtD
Haloperidol—Thrombocytopenia—Docetaxel—skin cancer	0.000224	0.00124	CcSEcCtD
Haloperidol—Tachycardia—Docetaxel—skin cancer	0.000223	0.00123	CcSEcCtD
Haloperidol—Skin disorder—Docetaxel—skin cancer	0.000222	0.00123	CcSEcCtD
Haloperidol—Vomiting—Temozolomide—skin cancer	0.000218	0.00121	CcSEcCtD
Haloperidol—Anorexia—Docetaxel—skin cancer	0.000218	0.0012	CcSEcCtD
Haloperidol—Rash—Temozolomide—skin cancer	0.000216	0.0012	CcSEcCtD
Haloperidol—Diarrhoea—Fluorouracil—skin cancer	0.000216	0.0012	CcSEcCtD
Haloperidol—Dermatitis—Temozolomide—skin cancer	0.000216	0.0012	CcSEcCtD
Haloperidol—Headache—Temozolomide—skin cancer	0.000215	0.00119	CcSEcCtD
Haloperidol—Hypotension—Docetaxel—skin cancer	0.000213	0.00118	CcSEcCtD
Haloperidol—Dizziness—Fluorouracil—skin cancer	0.000209	0.00116	CcSEcCtD
Haloperidol—Insomnia—Docetaxel—skin cancer	0.000207	0.00114	CcSEcCtD
Haloperidol—Nausea—Temozolomide—skin cancer	0.000204	0.00113	CcSEcCtD
Haloperidol—Dyspnoea—Docetaxel—skin cancer	0.000204	0.00113	CcSEcCtD
Haloperidol—Somnolence—Docetaxel—skin cancer	0.000203	0.00112	CcSEcCtD
Haloperidol—Vomiting—Fluorouracil—skin cancer	0.000201	0.00111	CcSEcCtD
Haloperidol—Dyspepsia—Docetaxel—skin cancer	0.000201	0.00111	CcSEcCtD
Haloperidol—Rash—Fluorouracil—skin cancer	0.000199	0.0011	CcSEcCtD
Haloperidol—Dermatitis—Fluorouracil—skin cancer	0.000199	0.0011	CcSEcCtD
Haloperidol—Decreased appetite—Docetaxel—skin cancer	0.000198	0.0011	CcSEcCtD
Haloperidol—Headache—Fluorouracil—skin cancer	0.000198	0.0011	CcSEcCtD
Haloperidol—Gastrointestinal disorder—Docetaxel—skin cancer	0.000197	0.00109	CcSEcCtD
Haloperidol—Constipation—Docetaxel—skin cancer	0.000195	0.00108	CcSEcCtD
Haloperidol—Feeling abnormal—Docetaxel—skin cancer	0.000188	0.00104	CcSEcCtD
Haloperidol—Nausea—Fluorouracil—skin cancer	0.000188	0.00104	CcSEcCtD
Haloperidol—ABCB1—head—skin cancer	0.000187	0.00238	CbGeAlD
Haloperidol—Body temperature increased—Docetaxel—skin cancer	0.00018	0.000999	CcSEcCtD
Haloperidol—Hypersensitivity—Docetaxel—skin cancer	0.000168	0.000931	CcSEcCtD
Haloperidol—Pruritus—Docetaxel—skin cancer	0.000162	0.000894	CcSEcCtD
Haloperidol—Diarrhoea—Docetaxel—skin cancer	0.000156	0.000865	CcSEcCtD
Haloperidol—Dizziness—Docetaxel—skin cancer	0.000151	0.000836	CcSEcCtD
Haloperidol—Vomiting—Docetaxel—skin cancer	0.000145	0.000804	CcSEcCtD
Haloperidol—Rash—Docetaxel—skin cancer	0.000144	0.000797	CcSEcCtD
Haloperidol—Dermatitis—Docetaxel—skin cancer	0.000144	0.000796	CcSEcCtD
Haloperidol—Headache—Docetaxel—skin cancer	0.000143	0.000792	CcSEcCtD
Haloperidol—Nausea—Docetaxel—skin cancer	0.000136	0.000751	CcSEcCtD
Haloperidol—ABCB1—lymph node—skin cancer	0.000131	0.00167	CbGeAlD
Haloperidol—HTR2A—GPCR downstream signaling—PTGER4—skin cancer	1.51e-05	0.000811	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PLIN2—skin cancer	1.51e-05	0.00081	CbGpPWpGaD
Haloperidol—HRH1—GPCR downstream signaling—PTGER4—skin cancer	1.51e-05	0.000809	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—TP53—skin cancer	1.5e-05	0.000801	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—SHH—skin cancer	1.49e-05	0.000798	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—SHH—skin cancer	1.49e-05	0.000796	CbGpPWpGaD
Haloperidol—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.46e-05	0.00078	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ENO2—skin cancer	1.44e-05	0.000773	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PTCH1—skin cancer	1.44e-05	0.000769	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—SMO—skin cancer	1.44e-05	0.000769	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PTCH1—skin cancer	1.41e-05	0.000756	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—SMO—skin cancer	1.41e-05	0.000756	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—SMO—skin cancer	1.41e-05	0.000755	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PTCH1—skin cancer	1.41e-05	0.000755	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—PTGER4—skin cancer	1.4e-05	0.000748	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.4e-05	0.000747	CbGpPWpGaD
Haloperidol—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	1.39e-05	0.000747	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—skin cancer	1.39e-05	0.000745	CbGpPWpGaD
Haloperidol—DRD1—Circadian rythm related genes—IL6—skin cancer	1.39e-05	0.000743	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—PTGER4—skin cancer	1.38e-05	0.000736	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—PTGER4—skin cancer	1.37e-05	0.000735	CbGpPWpGaD
Haloperidol—DRD3—Circadian rythm related genes—IL6—skin cancer	1.37e-05	0.000733	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SHH—skin cancer	1.37e-05	0.000731	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—RASA1—skin cancer	1.36e-05	0.000727	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SHH—skin cancer	1.34e-05	0.000716	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—KRAS—skin cancer	1.33e-05	0.000714	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—RASA1—skin cancer	1.33e-05	0.000712	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SHH—skin cancer	1.32e-05	0.000705	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GLI2—skin cancer	1.32e-05	0.000705	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—RASA1—skin cancer	1.31e-05	0.0007	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—SMO—skin cancer	1.3e-05	0.000693	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTCH1—skin cancer	1.3e-05	0.000693	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GLI2—skin cancer	1.3e-05	0.000693	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GLI2—skin cancer	1.29e-05	0.000692	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—CSPG4—skin cancer	1.29e-05	0.000691	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—SMO—skin cancer	1.27e-05	0.000679	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTCH1—skin cancer	1.27e-05	0.000679	CbGpPWpGaD
Haloperidol—HTR2A—SIDS Susceptibility Pathways—IL6—skin cancer	1.26e-05	0.000676	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—PTGER4—skin cancer	1.26e-05	0.000675	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SHH—skin cancer	1.26e-05	0.000673	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—MC1R—skin cancer	1.26e-05	0.000672	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—RASA1—skin cancer	1.25e-05	0.000668	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTCH1—skin cancer	1.25e-05	0.000668	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—SMO—skin cancer	1.25e-05	0.000668	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	1.24e-05	0.000664	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PLIN2—skin cancer	1.24e-05	0.000663	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—GLI1—skin cancer	1.24e-05	0.000662	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—MC1R—skin cancer	1.24e-05	0.000661	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—PTGER4—skin cancer	1.23e-05	0.000661	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—MC1R—skin cancer	1.23e-05	0.00066	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—CSPG4—skin cancer	1.22e-05	0.000653	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—GLI1—skin cancer	1.22e-05	0.000652	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—GLI1—skin cancer	1.22e-05	0.00065	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—PTGER4—skin cancer	1.21e-05	0.00065	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ENO2—skin cancer	1.21e-05	0.00065	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PLIN2—skin cancer	1.21e-05	0.000647	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.2e-05	0.000643	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—skin cancer	1.2e-05	0.000642	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—SMO—skin cancer	1.19e-05	0.000638	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTCH1—skin cancer	1.19e-05	0.000638	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SHH—skin cancer	1.19e-05	0.000634	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—RASA1—skin cancer	1.18e-05	0.00063	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SUFU—skin cancer	1.17e-05	0.000628	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SHH—skin cancer	1.17e-05	0.000626	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—RASA1—skin cancer	1.16e-05	0.000622	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—PTGER4—skin cancer	1.16e-05	0.000621	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SUFU—skin cancer	1.15e-05	0.000618	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SUFU—skin cancer	1.15e-05	0.000617	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—TP53—skin cancer	1.15e-05	0.000613	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PLIN2—skin cancer	1.14e-05	0.00061	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—HRAS—skin cancer	1.13e-05	0.000607	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PLIN2—skin cancer	1.13e-05	0.000605	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.13e-05	0.000604	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—SMO—skin cancer	1.12e-05	0.000601	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTCH1—skin cancer	1.12e-05	0.000601	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—FOXO4—skin cancer	1.11e-05	0.000596	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—SMO—skin cancer	1.11e-05	0.000593	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTCH1—skin cancer	1.11e-05	0.000593	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—PTGER4—skin cancer	1.09e-05	0.000585	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—FOXO4—skin cancer	1.09e-05	0.000584	CbGpPWpGaD
Haloperidol—GRIN2B—Developmental Biology—IL6—skin cancer	1.08e-05	0.000581	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—PTGER4—skin cancer	1.08e-05	0.000578	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—FOXO4—skin cancer	1.07e-05	0.000574	CbGpPWpGaD
Haloperidol—DRD2—Circadian rythm related genes—IL6—skin cancer	1.05e-05	0.000561	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—FOXO4—skin cancer	1.02e-05	0.000548	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.02e-05	0.000547	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	1.02e-05	0.000545	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—CSPG4—skin cancer	9.98e-06	0.000534	CbGpPWpGaD
Haloperidol—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	9.77e-06	0.000523	CbGpPWpGaD
Haloperidol—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	9.75e-06	0.000522	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—CSPG4—skin cancer	9.74e-06	0.000522	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—FOXO4—skin cancer	9.66e-06	0.000517	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PLIN2—skin cancer	9.65e-06	0.000517	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—FOXO4—skin cancer	9.53e-06	0.00051	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—CSPG4—skin cancer	9.18e-06	0.000492	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—CSPG4—skin cancer	9.1e-06	0.000487	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SHH—skin cancer	8.95e-06	0.000479	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—RASA1—skin cancer	8.89e-06	0.000476	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SHH—skin cancer	8.8e-06	0.000471	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SHH—skin cancer	8.78e-06	0.00047	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ENO2—skin cancer	8.78e-06	0.00047	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—RASA1—skin cancer	8.75e-06	0.000468	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—RASA1—skin cancer	8.73e-06	0.000467	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTCH1—skin cancer	8.48e-06	0.000454	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—SMO—skin cancer	8.48e-06	0.000454	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—ERCC2—skin cancer	8.39e-06	0.000449	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTCH1—skin cancer	8.35e-06	0.000447	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—SMO—skin cancer	8.35e-06	0.000447	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTCH1—skin cancer	8.33e-06	0.000446	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—SMO—skin cancer	8.33e-06	0.000446	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	8.31e-06	0.000445	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ENO2—skin cancer	8.29e-06	0.000444	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—PTGER4—skin cancer	8.26e-06	0.000442	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—PTGER4—skin cancer	8.12e-06	0.000435	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—PTGER4—skin cancer	8.11e-06	0.000434	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—CSPG4—skin cancer	7.78e-06	0.000416	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PLIN2—skin cancer	7.45e-06	0.000399	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TERT—skin cancer	7.44e-06	0.000398	CbGpPWpGaD
Haloperidol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	7.38e-06	0.000395	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—FOXO4—skin cancer	7.29e-06	0.00039	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TERT—skin cancer	7.28e-06	0.00039	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—FOXO4—skin cancer	7.18e-06	0.000384	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TERT—skin cancer	7.17e-06	0.000384	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—FOXO4—skin cancer	7.16e-06	0.000383	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—ERCC2—skin cancer	7.05e-06	0.000378	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TERT—skin cancer	6.84e-06	0.000366	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ENO2—skin cancer	6.79e-06	0.000363	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ENO2—skin cancer	6.62e-06	0.000355	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	6.49e-06	0.000347	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TERT—skin cancer	6.45e-06	0.000345	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TERT—skin cancer	6.37e-06	0.000341	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—NRAS—skin cancer	6.27e-06	0.000335	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ENO2—skin cancer	6.24e-06	0.000334	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ENO2—skin cancer	6.19e-06	0.000331	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—NRAS—skin cancer	6.14e-06	0.000329	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—NRAS—skin cancer	6.04e-06	0.000323	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—CSPG4—skin cancer	6e-06	0.000321	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—BRAF—skin cancer	5.89e-06	0.000315	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—BRAF—skin cancer	5.77e-06	0.000309	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—NRAS—skin cancer	5.76e-06	0.000309	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—BRAF—skin cancer	5.68e-06	0.000304	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—NRAS—skin cancer	5.44e-06	0.000291	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—BRAF—skin cancer	5.42e-06	0.00029	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—KRAS—skin cancer	5.39e-06	0.000289	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—NRAS—skin cancer	5.36e-06	0.000287	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	5.31e-06	0.000284	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ENO2—skin cancer	5.29e-06	0.000283	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—KRAS—skin cancer	5.28e-06	0.000283	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—KRAS—skin cancer	5.2e-06	0.000278	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—BRAF—skin cancer	5.11e-06	0.000274	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—ERCC2—skin cancer	5.1e-06	0.000273	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—BRAF—skin cancer	5.04e-06	0.00027	CbGpPWpGaD
Haloperidol—UGT1A9—Metabolism—PTGS2—skin cancer	5.03e-06	0.000269	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—KRAS—skin cancer	4.96e-06	0.000266	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TERT—skin cancer	4.87e-06	0.000261	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.84e-06	0.000259	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—ERCC2—skin cancer	4.82e-06	0.000258	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TERT—skin cancer	4.79e-06	0.000257	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TERT—skin cancer	4.78e-06	0.000256	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—KRAS—skin cancer	4.68e-06	0.00025	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—KRAS—skin cancer	4.62e-06	0.000247	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—HRAS—skin cancer	4.58e-06	0.000245	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—HRAS—skin cancer	4.49e-06	0.00024	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—HRAS—skin cancer	4.42e-06	0.000236	CbGpPWpGaD
Haloperidol—HTR1D—Signaling by GPCR—IL6—skin cancer	4.39e-06	0.000235	CbGpPWpGaD
Haloperidol—HTR1B—Signaling by GPCR—IL6—skin cancer	4.3e-06	0.00023	CbGpPWpGaD
Haloperidol—CYP3A7—Metabolism—PTGS2—skin cancer	4.23e-06	0.000226	CbGpPWpGaD
Haloperidol—DRD4—Signaling by GPCR—IL6—skin cancer	4.23e-06	0.000226	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—HRAS—skin cancer	4.22e-06	0.000226	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	4.14e-06	0.000221	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—NRAS—skin cancer	4.1e-06	0.00022	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ENO2—skin cancer	4.08e-06	0.000218	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—NRAS—skin cancer	4.04e-06	0.000216	CbGpPWpGaD
Haloperidol—HTR2B—Signaling by GPCR—IL6—skin cancer	4.04e-06	0.000216	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—NRAS—skin cancer	4.03e-06	0.000216	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—HRAS—skin cancer	3.98e-06	0.000213	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—ERCC2—skin cancer	3.94e-06	0.000211	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—HRAS—skin cancer	3.92e-06	0.00021	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—BRAF—skin cancer	3.86e-06	0.000207	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—ERCC2—skin cancer	3.85e-06	0.000206	CbGpPWpGaD
Haloperidol—DRD1—Signaling by GPCR—IL6—skin cancer	3.81e-06	0.000204	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—BRAF—skin cancer	3.8e-06	0.000203	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—BRAF—skin cancer	3.79e-06	0.000203	CbGpPWpGaD
Haloperidol—DRD3—Signaling by GPCR—IL6—skin cancer	3.76e-06	0.000201	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—NRAS—skin cancer	3.7e-06	0.000198	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—ERCC2—skin cancer	3.63e-06	0.000194	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—NRAS—skin cancer	3.63e-06	0.000194	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—ERCC2—skin cancer	3.59e-06	0.000192	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—NRAS—skin cancer	3.57e-06	0.000191	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—KRAS—skin cancer	3.53e-06	0.000189	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—KRAS—skin cancer	3.48e-06	0.000186	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—KRAS—skin cancer	3.47e-06	0.000186	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—NRAS—skin cancer	3.41e-06	0.000182	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—NRAS—skin cancer	3.21e-06	0.000172	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—KRAS—skin cancer	3.19e-06	0.000171	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—NRAS—skin cancer	3.17e-06	0.00017	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—KRAS—skin cancer	3.12e-06	0.000167	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—ERCC2—skin cancer	3.07e-06	0.000164	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—KRAS—skin cancer	3.07e-06	0.000164	CbGpPWpGaD
Haloperidol—CYP3A5—Metabolism—PTGS2—skin cancer	3.06e-06	0.000164	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—HRAS—skin cancer	3e-06	0.000161	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—HRAS—skin cancer	2.95e-06	0.000158	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—HRAS—skin cancer	2.95e-06	0.000158	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—KRAS—skin cancer	2.93e-06	0.000157	CbGpPWpGaD
Haloperidol—CYP1A1—Metabolism—PTGS2—skin cancer	2.89e-06	0.000155	CbGpPWpGaD
Haloperidol—DRD2—Signaling by GPCR—IL6—skin cancer	2.87e-06	0.000154	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—TP53—skin cancer	2.83e-06	0.000152	CbGpPWpGaD
Haloperidol—HTR2A—Signaling by GPCR—IL6—skin cancer	2.83e-06	0.000151	CbGpPWpGaD
Haloperidol—HRH1—Signaling by GPCR—IL6—skin cancer	2.82e-06	0.000151	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—TP53—skin cancer	2.77e-06	0.000148	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—KRAS—skin cancer	2.76e-06	0.000148	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—TP53—skin cancer	2.73e-06	0.000146	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—KRAS—skin cancer	2.73e-06	0.000146	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—HRAS—skin cancer	2.71e-06	0.000145	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—HRAS—skin cancer	2.65e-06	0.000142	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—HRAS—skin cancer	2.61e-06	0.00014	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—TP53—skin cancer	2.6e-06	0.000139	CbGpPWpGaD
Haloperidol—HTR1D—Signaling Pathways—IL6—skin cancer	2.59e-06	0.000139	CbGpPWpGaD
Haloperidol—HTR1B—Signaling Pathways—IL6—skin cancer	2.54e-06	0.000136	CbGpPWpGaD
Haloperidol—DRD4—Signaling Pathways—IL6—skin cancer	2.5e-06	0.000134	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—HRAS—skin cancer	2.49e-06	0.000133	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—TP53—skin cancer	2.46e-06	0.000132	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—NRAS—skin cancer	2.42e-06	0.00013	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—TP53—skin cancer	2.42e-06	0.00013	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—NRAS—skin cancer	2.39e-06	0.000128	CbGpPWpGaD
Haloperidol—HTR2B—Signaling Pathways—IL6—skin cancer	2.38e-06	0.000128	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—NRAS—skin cancer	2.38e-06	0.000127	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—ERCC2—skin cancer	2.37e-06	0.000127	CbGpPWpGaD
Haloperidol—CYP2C19—Metabolism—PTGS2—skin cancer	2.36e-06	0.000127	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—HRAS—skin cancer	2.35e-06	0.000126	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—HRAS—skin cancer	2.32e-06	0.000124	CbGpPWpGaD
Haloperidol—ABCB1—Metabolism—PTGS2—skin cancer	2.31e-06	0.000123	CbGpPWpGaD
Haloperidol—DRD1—Signaling Pathways—IL6—skin cancer	2.25e-06	0.00012	CbGpPWpGaD
Haloperidol—DRD3—Signaling Pathways—IL6—skin cancer	2.22e-06	0.000119	CbGpPWpGaD
Haloperidol—CYP2D6—Metabolism—PTGS2—skin cancer	2.17e-06	0.000116	CbGpPWpGaD
Haloperidol—CYP2C9—Metabolism—PTGS2—skin cancer	2.16e-06	0.000115	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—KRAS—skin cancer	2.09e-06	0.000112	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—KRAS—skin cancer	2.05e-06	0.00011	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—KRAS—skin cancer	2.05e-06	0.00011	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—TP53—skin cancer	1.85e-06	9.93e-05	CbGpPWpGaD
Haloperidol—CYP1A2—Metabolism—PTGS2—skin cancer	1.84e-06	9.86e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—TP53—skin cancer	1.82e-06	9.77e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—TP53—skin cancer	1.82e-06	9.75e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—HRAS—skin cancer	1.77e-06	9.5e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—HRAS—skin cancer	1.75e-06	9.34e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—HRAS—skin cancer	1.74e-06	9.32e-05	CbGpPWpGaD
Haloperidol—DRD2—Signaling Pathways—IL6—skin cancer	1.7e-06	9.09e-05	CbGpPWpGaD
Haloperidol—HTR2A—Signaling Pathways—IL6—skin cancer	1.67e-06	8.94e-05	CbGpPWpGaD
Haloperidol—HRH1—Signaling Pathways—IL6—skin cancer	1.67e-06	8.92e-05	CbGpPWpGaD
Haloperidol—CYP3A4—Metabolism—PTGS2—skin cancer	1.42e-06	7.61e-05	CbGpPWpGaD
